CN102342943A - 一种全新口服固体药用组合物及其制备方法 - Google Patents
一种全新口服固体药用组合物及其制备方法 Download PDFInfo
- Publication number
- CN102342943A CN102342943A CN2011101981684A CN201110198168A CN102342943A CN 102342943 A CN102342943 A CN 102342943A CN 2011101981684 A CN2011101981684 A CN 2011101981684A CN 201110198168 A CN201110198168 A CN 201110198168A CN 102342943 A CN102342943 A CN 102342943A
- Authority
- CN
- China
- Prior art keywords
- hydrochlorothiazide
- levamlodipine
- losartan potassium
- weight portion
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000007787 solid Substances 0.000 title claims abstract description 9
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 175
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 165
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 80
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 80
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 claims abstract description 77
- 229950008554 levamlodipine Drugs 0.000 claims abstract description 76
- 239000002083 C09CA01 - Losartan Substances 0.000 claims abstract description 73
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 71
- 229960000519 losartan potassium Drugs 0.000 claims abstract description 65
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 40
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 40
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 40
- 229920000881 Modified starch Polymers 0.000 claims abstract description 40
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 40
- 239000008101 lactose Substances 0.000 claims abstract description 40
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 40
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 40
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 40
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 40
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 74
- 239000013078 crystal Substances 0.000 claims description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 42
- 229950005770 hyprolose Drugs 0.000 claims description 39
- 239000011248 coating agent Substances 0.000 claims description 37
- 238000000576 coating method Methods 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 32
- 235000012239 silicon dioxide Nutrition 0.000 claims description 25
- 239000011812 mixed powder Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- 239000011259 mixed solution Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 238000005070 sampling Methods 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 229960001866 silicon dioxide Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000012065 filter cake Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 229960001375 lactose Drugs 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 238000001291 vacuum drying Methods 0.000 claims description 9
- 229910017488 Cu K Inorganic materials 0.000 claims description 8
- 229910017541 Cu-K Inorganic materials 0.000 claims description 8
- 230000005260 alpha ray Effects 0.000 claims description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 7
- 239000011976 maleic acid Substances 0.000 claims description 7
- 229940098895 maleic acid Drugs 0.000 claims description 7
- 239000003595 mist Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 37
- 206010020772 Hypertension Diseases 0.000 abstract description 19
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 20
- 229960000528 amlodipine Drugs 0.000 description 20
- 230000036772 blood pressure Effects 0.000 description 18
- 238000011282 treatment Methods 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000024172 Cardiovascular disease Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000003276 anti-hypertensive effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 6
- 239000002220 antihypertensive agent Substances 0.000 description 6
- 229940127088 antihypertensive drug Drugs 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940033901 hydrochlorothiazide / losartan Drugs 0.000 description 6
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 6
- 229940048175 losartan potassium 50 mg Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 5
- 239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007916 tablet composition Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010051467 Nephrectasia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000029547 smooth muscle hypertrophy Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110198168 CN102342943B (zh) | 2011-07-14 | 2011-07-14 | 一种口服固体药用组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110198168 CN102342943B (zh) | 2011-07-14 | 2011-07-14 | 一种口服固体药用组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102342943A true CN102342943A (zh) | 2012-02-08 |
CN102342943B CN102342943B (zh) | 2013-07-10 |
Family
ID=45542265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110198168 Expired - Fee Related CN102342943B (zh) | 2011-07-14 | 2011-07-14 | 一种口服固体药用组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102342943B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115666564A (zh) * | 2020-06-09 | 2023-01-31 | 韩美药品株式会社 | 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101450211A (zh) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 复方降压制剂 |
CN102008485A (zh) * | 2009-07-11 | 2011-04-13 | 邬林祥 | 一种治疗高血压含氯沙坦的复方制剂 |
CN102038687A (zh) * | 2009-07-14 | 2011-05-04 | 邬林祥 | 一种治疗高血压含氨氯地平和氯沙坦的复方制剂 |
-
2011
- 2011-07-14 CN CN 201110198168 patent/CN102342943B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101450211A (zh) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 复方降压制剂 |
CN102008485A (zh) * | 2009-07-11 | 2011-04-13 | 邬林祥 | 一种治疗高血压含氯沙坦的复方制剂 |
CN102038687A (zh) * | 2009-07-14 | 2011-05-04 | 邬林祥 | 一种治疗高血压含氨氯地平和氯沙坦的复方制剂 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115666564A (zh) * | 2020-06-09 | 2023-01-31 | 韩美药品株式会社 | 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102342943B (zh) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102335176B (zh) | 一种口服固体药用组合物及其制备方法 | |
CN100551442C (zh) | 含有钙通道阻滞剂和b族维生素的药物组合物及其用途 | |
CN101347427A (zh) | 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方 | |
CN101033245B (zh) | 具栖冬青苷的制备方法及应用 | |
CN102327272B (zh) | 一种口服固体药用组合物及其制备方法 | |
CN102349902B (zh) | 一种含有左旋氨氯地平和坎地沙坦酯的药物组合物及其制备方法 | |
CN102342942A (zh) | 一种全新口服固体药用组合物及其制备方法 | |
CN102335178B (zh) | 一种口服固体药用组合物及其制备方法 | |
CN102342943B (zh) | 一种口服固体药用组合物及其制备方法 | |
CN102327271B (zh) | 一种左旋氨氯地平氢氯噻嗪药用组合物及其制备方法 | |
CN102370965A (zh) | 一种含有左旋氨氯地平药学上可接受的盐与培哚普利药学上可接受的盐的药物组合物 | |
CN102266333B (zh) | 一种含有左旋氨氯地平和阿托伐他汀钙的全新药用组合物及其制备方法 | |
CN102335177B (zh) | 一种口服固体药用组合物及其制备方法 | |
CN115124420B (zh) | 大黄酸与苦参碱共晶物水合物及制备方法和其组合物与用途 | |
CN101543483B (zh) | 西尼地平胶囊及其制备方法和质量检测方法 | |
CN103230594A (zh) | α-葡萄糖苷酶抑制剂和B族维生素的药物组合物 | |
CN104208034B (zh) | 一种格列美脲药物组合物片剂、制备方法及其应用 | |
CN102342948B (zh) | 一种全新口服固体药用组合物及其制备方法 | |
CN101766611A (zh) | 一种左旋氨氯地平或其可药用盐和β受体阻滞剂的药物组合物及其应用 | |
CN102526739B (zh) | 治疗糖尿病的药物组合物及其应用 | |
CN101785781B (zh) | 一种左旋氨氯地平或其可药用盐和黑木耳多糖的药物组合物及其应用 | |
CN102266331B (zh) | 一种含有左旋氨氯地平和氯沙坦钾的全新药用组合物及其制备方法 | |
CN102329283B (zh) | 氢氯噻嗪晶体及其坎地沙坦酯氢氯噻嗪药用组合物 | |
CN103006651A (zh) | 一种含奥美沙坦酯和氨氯地平的片剂及其制备方法 | |
CN102349921B (zh) | 一种全新的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 570216 No. 8 factory building, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee after: HAINAN JINRUI PHARMACEUTICAL Co.,Ltd. Address before: 570216 No. 8 factory building, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee before: HAINAN JINRUI PHARMACEUTICAL Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN GAOSHENG MEDICINE TECHNOLOGY DEVELOPMENT CO Free format text: FORMER OWNER: HAINAN JINRUI PHARMACEUTICAL CO., LTD. Effective date: 20150326 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570216 HAIKOU, HAINAN PROVINCE TO: 570208 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150326 Address after: 101 room 12, 66 Jiangnan City, Baoan Heping Road, 570208, Hainan, Haikou Patentee after: Hainan Gaosheng Pharmaceutical R & D Co.,Ltd. Address before: 570216 No. 8 factory building, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee before: HAINAN JINRUI PHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160602 Address after: 570216 No. 8 factory building, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee after: HAINAN JINRUI PHARMACEUTICAL Co.,Ltd. Address before: 101 room 12, 66 Jiangnan City, Baoan Heping Road, 570208, Hainan, Haikou Patentee before: Hainan Gaosheng Pharmaceutical R & D Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130710 |
|
CF01 | Termination of patent right due to non-payment of annual fee |